Trial Profile
A Phase 1 Pharmacokinetic and Pharmacodynamic Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Edralbrutinib (Primary) ; Ublituximab (Primary) ; Umbralisib (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- Sponsors TG Therapeutics Inc
- 21 Jun 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
- 21 Jun 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 10 Aug 2022 Status changed from recruiting to active, no longer recruiting.